[go: up one dir, main page]

WO2002062767A1 - Novel quinazoline derivatives - Google Patents

Novel quinazoline derivatives Download PDF

Info

Publication number
WO2002062767A1
WO2002062767A1 PCT/JP2002/001045 JP0201045W WO02062767A1 WO 2002062767 A1 WO2002062767 A1 WO 2002062767A1 JP 0201045 W JP0201045 W JP 0201045W WO 02062767 A1 WO02062767 A1 WO 02062767A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
quinazoline derivatives
general formula
following general
novel quinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/001045
Other languages
French (fr)
Japanese (ja)
Inventor
Sumitsugu Kisanuki
Hideyuki Tomizawa
Yoshiaki Isobe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eneos Corp
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Japan Energy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Japan Energy Corp filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of WO2002062767A1 publication Critical patent/WO2002062767A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Medicinal compositions for preventing or treating inflammatory diseases caused by bacterial DNA which contain as the active ingredient quinazoline derivatives represented by the following general formula (I), etc.: (I) wherein R?5, R6, R7 and R8¿ represent each hydrogen, etc.; R2 represents aryl, heteroaryl, etc.; n is 0 or 1; and X represents a group of the following general formula (a) or (b): (a) (b) wherein P represents C¿2-6? alkylene, etc.; R?9 and R10¿ represent hydrogen, etc.; Y represents CHR11 (wherein R11 represents hydrogen, etc.), etc.; and Z represents hydrogen, etc.
PCT/JP2002/001045 2001-02-07 2002-02-07 Novel quinazoline derivatives Ceased WO2002062767A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-30973 2001-02-07
JP2001030973 2001-02-07

Publications (1)

Publication Number Publication Date
WO2002062767A1 true WO2002062767A1 (en) 2002-08-15

Family

ID=18895118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/001045 Ceased WO2002062767A1 (en) 2001-02-07 2002-02-07 Novel quinazoline derivatives

Country Status (1)

Country Link
WO (1) WO2002062767A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523238A (en) * 2003-04-09 2006-10-12 エクセリクシス， インク． TIE-2 modulator and usage
JP2007524615A (en) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー Low molecular weight Toll-like receptor (TLR) antagonist
WO2007117161A1 (en) * 2006-04-07 2007-10-18 Auckland Uniservices Limited Substituted ring fused azines and their use in cancer therapy
JP2008526734A (en) * 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド Quinazoline derivatives effective in preventing diabetes and obesity
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US7625908B2 (en) 2003-11-13 2009-12-01 Astrazeneca Ab Quinazoline derivatives
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
US7838530B2 (en) 2003-09-25 2010-11-23 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
US7910731B2 (en) 2002-03-30 2011-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
WO2012046207A1 (en) * 2010-10-08 2012-04-12 Paraco Technology Limited Anti-parasitic substituted ring fused azine compounds
WO2013003586A1 (en) 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Quinazolines as therapeutic compounds and related methods of use
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
US8575184B2 (en) 2009-09-03 2013-11-05 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
JP2014141522A (en) * 2008-03-13 2014-08-07 Guangzhou Institute Of Biomedicine And Health Chinese Academy Of Sciences Estrogen related receptor modulator compound and use thereof
WO2015019121A1 (en) * 2013-08-09 2015-02-12 Vichem Chemie Kutató Kft. Styryl quinazoline derivatives as pharmaceutically active agents
US9073890B2 (en) 2009-12-31 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
CN111253325A (en) * 2020-03-25 2020-06-09 广州大学 Amino quinazoline aryl piperazine compound and pharmaceutical composition and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192235A (en) * 1992-07-15 1994-07-12 Ono Pharmaceut Co Ltd 4-aminoquinazoline derivative, its production and medicine containing the same derivative
WO1999009986A1 (en) * 1997-08-22 1999-03-04 Kyowa Hakko Kogyo Co., Ltd. 4-aminoquinazoline derivatives
DE19756388A1 (en) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh New 2-aryl-4-amino-6,7-di:methoxy-quinazoline derivatives useful as guanylate cyclase activators for treating cardiovascular diseases, etc.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192235A (en) * 1992-07-15 1994-07-12 Ono Pharmaceut Co Ltd 4-aminoquinazoline derivative, its production and medicine containing the same derivative
WO1999009986A1 (en) * 1997-08-22 1999-03-04 Kyowa Hakko Kogyo Co., Ltd. 4-aminoquinazoline derivatives
DE19756388A1 (en) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh New 2-aryl-4-amino-6,7-di:methoxy-quinazoline derivatives useful as guanylate cyclase activators for treating cardiovascular diseases, etc.

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910731B2 (en) 2002-03-30 2011-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US8343982B2 (en) 2002-03-30 2013-01-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same
JP4895806B2 (en) * 2003-04-09 2012-03-14 エクセリクシス， インク． TIE-2 modulator and usage
JP2006523238A (en) * 2003-04-09 2006-10-12 エクセリクシス， インク． TIE-2 modulator and usage
JP2007524615A (en) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー Low molecular weight Toll-like receptor (TLR) antagonist
US7410975B2 (en) 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US7838530B2 (en) 2003-09-25 2010-11-23 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
US7625908B2 (en) 2003-11-13 2009-12-01 Astrazeneca Ab Quinazoline derivatives
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
JP2008526734A (en) * 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド Quinazoline derivatives effective in preventing diabetes and obesity
JP2009533338A (en) * 2006-04-07 2009-09-17 オークランド ユニサーヴィスィズ リミテッド Substituted ring fused azines and their use in cancer therapy
WO2007117161A1 (en) * 2006-04-07 2007-10-18 Auckland Uniservices Limited Substituted ring fused azines and their use in cancer therapy
US8399461B2 (en) 2006-11-10 2013-03-19 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
US8772298B2 (en) 2008-02-07 2014-07-08 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP2014141522A (en) * 2008-03-13 2014-08-07 Guangzhou Institute Of Biomedicine And Health Chinese Academy Of Sciences Estrogen related receptor modulator compound and use thereof
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US9822096B2 (en) 2009-09-03 2017-11-21 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US10214511B2 (en) 2009-09-03 2019-02-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US11008306B2 (en) 2009-09-03 2021-05-18 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US10676460B2 (en) 2009-09-03 2020-06-09 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8575184B2 (en) 2009-09-03 2013-11-05 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9458114B2 (en) 2009-09-03 2016-10-04 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9161934B2 (en) 2009-10-22 2015-10-20 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
US9073890B2 (en) 2009-12-31 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
EP3056207A1 (en) 2009-12-31 2016-08-17 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
US9630947B2 (en) 2009-12-31 2017-04-25 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use
WO2012046207A1 (en) * 2010-10-08 2012-04-12 Paraco Technology Limited Anti-parasitic substituted ring fused azine compounds
WO2013003586A1 (en) 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Quinazolines as therapeutic compounds and related methods of use
US9951029B2 (en) 2013-08-09 2018-04-24 Vichem Chemie Kutató Kft. Styryl quinazoline derivatives as pharmaceutically active agents
WO2015019121A1 (en) * 2013-08-09 2015-02-12 Vichem Chemie Kutató Kft. Styryl quinazoline derivatives as pharmaceutically active agents
CN111253325A (en) * 2020-03-25 2020-06-09 广州大学 Amino quinazoline aryl piperazine compound and pharmaceutical composition and application thereof

Similar Documents

Publication Publication Date Title
WO2002062767A1 (en) Novel quinazoline derivatives
ES2187473T3 (en) TRIARYLIMIDAZOLES.
TR200200749T2 (en) Quinazoline compounds and pharmaceutical compositions containing them.
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
PL368739A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
BG106390A (en) Novel spiro compounds
CA2414095A1 (en) Novel compounds
WO2002024686A3 (en) Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
NO992821L (en) Ketobenzamides as Calpain Inhibitors
WO2001032654A3 (en) Novel heterocyclic compounds and their use as medicines
SE9904652D0 (en) Novel Compounds
EP1702917A4 (en) AMIDE DERIVATIVE AND MEDICINAL PRODUCT
NO971471L (en) New carboxamides with fungicidal activity
EP1396493A4 (en) Heterocyclic compounds
DE60118225D1 (en) CHINOLIN AND CHINAZOLINE DERIVATIVES AND THEIR USE AS FARNESYL TRANSFERASE INHIBITORS
SE9904108D0 (en) New compounds
CA2336412A1 (en) Medicament for treatment of diabetes
WO2003051274A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
EP0765865A4 (en) 2-acylaminopropanol compound and medicinal composition
WO2003053971A8 (en) Pyridoquinoxaline antivirals
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
NO20052182L (en) New connections
SE0101038D0 (en) Novel compounds
YU33202A (en) Oxime o-ether compounds and fungicides for agricultural and horticultural use
WO2002088125A3 (en) Triazolopyrimidines having a fungicidal effect

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP